Publicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (19)

2024

  1. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

    Journal of Clinical Oncology, Vol. 42, Núm. 1, pp. 47-58

  2. The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma

    Nature Cancer

2023

  1. Overall Survival with Maintenance Olaparib at a 7-Year Follow-Up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 3, pp. 609-617

  2. Overall Survival with Maintenance Olaparib at a 7-Year Follow-up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

    Obstetrical and Gynecological Survey

  3. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

    Nature, Vol. 616, Núm. 7957, pp. 553-562

2022

  1. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial

    European Journal of Cancer, Vol. 174, pp. 221-231

  2. Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis

    Gynecologic Oncology, Vol. 164, Núm. 3, pp. 498-504

  3. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268

  4. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

    Therapeutic Advances in Medical Oncology, Vol. 14

2021

  1. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

    European Journal of Cancer, Vol. 152, pp. 68-77

  2. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 12, pp. 1721-1731

  3. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 5, pp. 632-642

  4. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

    Gynecologic Oncology, Vol. 163, Núm. 1, pp. 41-49

2020

  1. Efficacy of Maintenance Olaparib for Patients with Newly Diagnosed Advanced Ovarian Cancer with a BRCA Mutation: Subgroup Analysis Findings from the SOLO1 Trial

    Journal of Clinical Oncology, Vol. 38, Núm. 30, pp. 3528-3537

2019

  1. Cost–utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain

    Clinical and Translational Oncology, Vol. 21, Núm. 8, pp. 1076-1084

  2. Identification of resistance pathways specific to malignancy using organoid models of pancreatic cancer

    Clinical Cancer Research, Vol. 25, Núm. 22, pp. 6742-6755

  3. Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Obstetrical and Gynecological Survey

2018

  1. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer

    New England Journal of Medicine, Vol. 379, Núm. 26, pp. 2495-2505

2016

  1. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma

    Clinical Cancer Research